passionate childhood cancer advocate · patrick sullivan, chair, childhood cancer canada. you have...
TRANSCRIPT
![Page 1: Passionate Childhood Cancer Advocate · Patrick Sullivan, Chair, Childhood Cancer Canada. You Have To Recognize A Problem To Address It • Proportion of pediatric trials in oncology](https://reader034.vdocument.in/reader034/viewer/2022050601/5fa8c9c680a35455b703109c/html5/thumbnails/1.jpg)
Passionate Childhood Cancer Advocate
Patrick Sullivan, Chair, Childhood Cancer Canada
![Page 2: Passionate Childhood Cancer Advocate · Patrick Sullivan, Chair, Childhood Cancer Canada. You Have To Recognize A Problem To Address It • Proportion of pediatric trials in oncology](https://reader034.vdocument.in/reader034/viewer/2022050601/5fa8c9c680a35455b703109c/html5/thumbnails/2.jpg)
You Have To Recognize A Problem To Address It
![Page 3: Passionate Childhood Cancer Advocate · Patrick Sullivan, Chair, Childhood Cancer Canada. You Have To Recognize A Problem To Address It • Proportion of pediatric trials in oncology](https://reader034.vdocument.in/reader034/viewer/2022050601/5fa8c9c680a35455b703109c/html5/thumbnails/3.jpg)
• Proportion of pediatric trials in oncology has been decreasing over time, especially for those which are investigator-led (rather than industry-sponsored)
The Access Problem In Canada
3
2010 2014 2018
Total # of CTAs 827 806 791
Total pediatric CTAs 136 109 134
% oncology 19.9% 16.5% 11.9%
Academic-sponsored oncology 14.0% 12.8% 4.5%
Industry-sponsored oncology 6.6% 3.7% 7.5%
![Page 4: Passionate Childhood Cancer Advocate · Patrick Sullivan, Chair, Childhood Cancer Canada. You Have To Recognize A Problem To Address It • Proportion of pediatric trials in oncology](https://reader034.vdocument.in/reader034/viewer/2022050601/5fa8c9c680a35455b703109c/html5/thumbnails/4.jpg)
We Are Collectively Working Hard to Address The Access Problem• Excellent working relationship with Clinicians & C17• Excellent working relationship with Health Canada
• Efforts to modernize Clinical Trial regulatory structure• Change in approach to off-label drugs in Clinical Trials• Continue to meet with informally
• Reminding everyone that we need to start with Why and then move to what and how
• $30 Million Federal Government Commitment To Pediatric Cancer• Continuing to diagnose the problem
![Page 5: Passionate Childhood Cancer Advocate · Patrick Sullivan, Chair, Childhood Cancer Canada. You Have To Recognize A Problem To Address It • Proportion of pediatric trials in oncology](https://reader034.vdocument.in/reader034/viewer/2022050601/5fa8c9c680a35455b703109c/html5/thumbnails/5.jpg)
Way(s) Forward to Further Address What An Access Gap That I Believe Will Get Worse• Embed patients in the international regulatory cooperative efforts that
Alysha spoke to• Keep the focus on Why• Drive a respectful sense of urgency• Think the problem differently
• Use the Accelerate forum to combat the Law of Unintended Consequences• Develop relationships with Payors• Understand both the problems and the opportunities from the perspective
of Industry • Play to our strengths and embrace the possibilities inherent in an
International Pediatric Oncology Regulatory Sandbox
![Page 6: Passionate Childhood Cancer Advocate · Patrick Sullivan, Chair, Childhood Cancer Canada. You Have To Recognize A Problem To Address It • Proportion of pediatric trials in oncology](https://reader034.vdocument.in/reader034/viewer/2022050601/5fa8c9c680a35455b703109c/html5/thumbnails/6.jpg)
Thank You!